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Background: 
 Testosterone therapy, also known as male hormone replacement therapy has commonly 
been prescribed for older men since the 1950’s. Low testosterone (low T) in men has been linked 
with elevated cardiovascular risk factors, cardiovascular events, and increased cardiovascular 
mortality1. However, in 2014 the Food and Drug Administration (FDA) issued a warning 
regarding therapeutic testosterone use for age related hypogonadism or low T regarding 
increased cardiovascular related events and stroke2. Although studied extensively, providers 
continue to disagree as to its safety and effectiveness especially considering this recent 
recommendation. Therefore, the purpose of this clinical review is to discuss diagnosis and 
treatment options for men with low T while evaluating systematic reviews analyzing 
cardiovascular risk.    
   Unlike female menopause, male hypogonadism does not universally develop in men. 
Low T, also known as hypogonadism or andropause, is associated with a lower quality of life 
and is currently estimated to affect as many as 38-40% of men in their lifetime3. To treat men for 
andropause, Testosterone therapy (TTh) is prescribed in several different forms such as 
intramuscular (IM) injections, topical creams, subcutaneous (SC) pellets, oral pills, and 
transdermal patches. With sales projected to reach 3.2 billion by 20224, TTh is marketed to older 
men to treat multiple symptoms including: 1) fatigue, 2) mood, 3) muscle mass, 4) strength, and 
5) sexual dysfunction as well as prevention of worsening heart disease5. But, in multiple reviews 
the conclusion is that there is little benefit that outweighs the risks associated with TTh. These 
risks include cardiovascular events such as myocardial infarction (MI) and stroke as well as 
prostatic hyperplasia, and cancer. With the widespread use of TTh, more definitive 
determinations need to be made regarding the potential dangers of TTh.  
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 It is important to define male hypogonadism. There are an extensive range of natural and 
disease processes responsible for hypogonadism in men, normal aging being the most common 
cause. Normal secretion of testosterone is regulated by the hypothalamic-pituitary-gonadal axis. 
Approximately every 90 minutes, the hypothalamus secretes gonadotropin releasing hormone 
(GnRH) to the pituitary which releases luteinizing hormone (LH) to the testicles where Leydig 
cells then release testosterone. Any disruption in this process can lead to hypogonadism. Primary 
hypogonadism refers to dysfunction in the testicles, while secondary hypogonadism refers to 
dysfunction in the hypothalamus or pituitary 6.  
 
Diagnosis of Hypogonadism: 
 There has been debate over what range of testosterone levels indicate clinically relevant 
hypogonadism and the subsequent need for TTh. The most common distinction currently in use 
is serum testosterone levels < 300 ng/dL 7. However, the ranges considered normal may be 
broader. A new systematic review of previous data verified a new range from 2.5% at 264 ng/dL 
to the 97% at 916 ng/dL, with a median of 530 ng/dL by cross-calibration of assays from four 
major epidemiological studies8.  
 The diagnosis of male hypogonadism begins with a symptomatic patient presentation 
with complaints that may include: 1) low libido, 2) decreased sexual activity, 3) reduction in 
spontaneous erections, 4) gynecomastia, and 5) loss of body hair. When reproduction is a goal, a 
patient may present with infertility and low sperm counts. According to the European Male 
Aging Study (EMAS), the most sensitive triad of symptoms related to physiologically low T 
levels are reduced sexual fantasies, reduced nocturnal and morning erections, and erectile 
dysfunction9. Associated symptoms include fatigue, increased body fat, decreased muscle mass, 
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and decreased overall sense of wellbeing. Patients presenting with these complaints are therefore 
most appropriate to screen for low testosterone10. Conversely, it is not recommended to screen 
asymptomatic men for low T.  
 Once a patient is identified appropriate for screening, the total serum testosterone is 
tested in the morning with a repeat test to confirm since up to 30% of men can have normal 
testosterone level on repeat testing10. Free or bioavailable testosterone levels should also be 
tested to determine if an issue with sex hormone-binding globulin (SHBG) is suspected. A 
normal serum free testosterone ranges in healthy individuals from 5–9 pg/ml (0.17–0.31 
nmol/liter)10. Conditions associated with increased SHBG include aging, hepatic cirrhosis, 
obesity, diabetes, and hyperthyroidism as well as use of anti-convulsant and estrogens10. The 
presence of large amounts of SHBG will bind free testosterone, preventing its use by the body. 
Once morning low testosterone is confirmed, LH and FSH levels should be checked to determine 
if the source of deficiency is primary or secondary. Low testosterone with elevated LH and FSH 
levels indicates a primary dysfunction involving the testes. Low testosterone and low or normal 
levels of LH and FSH indicates a secondary dysfunction from the hypothalamus and/or pituitary. 
The current acceptable testosterone level to treat is <280-300 ng/dL10.   
  
Treatment of Hypogonadism: 
 Currently there is no evidence that any specific modality of treatment has greater 
therapeutic effect or more side effects. The choice of form of treatment is left to provider and 
patient preference. According to the 2010 Endocrine Society clinical practice guidelines10, 
choices of testosterone treatments include 1) injectables, 2) oral pills, 3) creams and gels, 4) 
transdermal patches, 5) buccal tablets, and 6) implantable pellets. Injectable choices are 
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testosterone enanthate or cypionate 75-100mg weekly or 150-200mg every two weeks. 
Testosterone undecanoate 1000 mg every 12 weeks. Oral testosterone undecanoate 40mg – 80mg 
taken once, twice, or three times daily. Transdermal testosterone patches are 2.5 mg and can be 
applied to the back, thigh, or upper arm. 5 to 10 grams of 1% testosterone gel is applied to the 
chest daily. 30 milligram testosterone tablets are applied to the buccal mucosa every 12 hours. 
Finally, testosterone pellets in various dosages can be injected under the skin every 3 to 6 
months.  
 
Methods: 
 In order to evaluate the current literature on cardiovascular risk associated with TTh, a 
study search was conducted through Pubmed, TRIP database, Cochrane Library, and Clinical 
Key utilizing key terms [testosterone, therapy, cardiovascular, risk, systematic review, meta-
analysis]. The search was restricted to systematic reviews with meta-analysis within the last 10 
years (2007 – 2017). Selected studies included only those primarily reviewing placebo-controlled 
randomized control trials (RCT’s) of testosterone therapy with meta-analysis where evaluation of 
cardiovascular risk and/or events was the primary or secondary outcome of the study or one of 
the study arms. For each review we have reproduced the meta-analysis reported excluding 
Haddad et al. Forest plots of meta-analysis located in appendix 1. 
   
Results 
 The above search criteria from Pubmed, TRIP database, Cochrane library of systematic 
reviews, and Clinical key yielded 7 systematic reviews with meta-analysis that met inclusion 
criteria evaluating TTh association with cardiovascular related events compared to placebo. 
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 Haddad et al11 (2007) conducted a systematic review and meta-analysis of only 
published RCT’s to assess cardiovascular (CV) risk factors, CV events, and CV end points for 
TTh vs placebo. The study reviewed 30 RCT’s from 1966 to 2004, with total population of 1642 
men, 808 receiving TTh. Baseline low testosterone levels were defined as <300 ng/dL or 10.4 
nmol/L. Quality assessment was determined based on the randomization, concealment of 
allocation, blinding, and loss to follow up. The authors noted that overall study quality was 
difficult to ascertain due to scant reporting on methods to limit bias. A full 20% of the studies 
inadequately reported allocation concealment and 9% did not address loss to follow up. No 
additional information pertaining to quality and bias assessment was divulged. The authors did 
not specify GRADE criteria, however, they stated that the available evidence is inconsistent, 
imprecise, and poorly reported. Statistical analysis for the meta-analysis was conducted using the 
random-effects method and I2 statistic for heterogeneity across studies. Results of the study 
regarding CV events with TTh revealed an odds ratio (OR) of 1.82 (95% CI, 0.78 to 4.23) 
slightly favoring placebo. 
 
 Fernandez-Balsells et al12 (2010) evaluated death, CV events, prostatic effects, and 
erythrocytosis adverse effects of TTh with a systematic review and meta-analysis of comparative 
RCT’s and non-randomized control trials. Cardiovascular events evaluated included death, 
coronary events, stroke, and peripheral vascular events. A total of 51 studies were included in the 
review. Inclusion criteria required comparison of TTh to placebo in adult men with low or low to 
normal testosterone levels for a minimum of 3 months. Baseline testosterone levels were rated 
low if <300 ng/dL or 10.4 nmol/l. Exclusions were made for studies with additional hormone or 
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drug administration as well as outcomes not of interest. Studies covered 2003 to 2008 initially 
then expanded to include studies from 1981 to 2004 for HIV/AIDS population inclusion. 
GRADE criteria were used to evaluate quality of evidence for the randomized trials. Assessment 
was completed for randomization, allocation concealment, blinding, and loss to follow up. 
Quality of the studies included was deemed to be of low to medium quality. Twenty-eight studies 
failed to report allocation concealment and 34 did not report blinding of outcome assessors. 
Meta-analysis estimated relative risk (RR) for dichotomous outcomes and weighted mean 
difference for continuous outcomes pooled across studies using the random-effects model. 
Heterogeneity was used across studies using I2 statistic for inconsistency. Overall, results for 
cardiovascular outcomes showed no significant differences between testosterone vs placebo 
groups (figure 1.).    
 
 Xu et al13 (2013) utilized 27 RCT’s totaling 2994 men comparing TTh to placebo for 
cardiovascular events for >12 weeks. Inclusion criteria consisted of randomized, placebo-
controlled trials that evaluated cardiovascular events by study arm with testosterone as the sole 
hormone administered. Exclusion criteria included studies that only reported events in the TTh 
arm and not the placebo as well as trials of less than 12 weeks. Cardiovascular events included 
any reportable by the authors with serious events defined as death, cardiac hospitalization, 
medical/surgical intervention, myocardial infarction, coronary artery disease (CAD), unstable 
angina, arrhythmias, stroke, or congestive heart failure. Study search was conducted through 
2012. Quality assessment evaluated randomization, allocation concealment, blinding, and 
masking utilizing the Delphi list. While the authors did not give a direct quality rating, quality 
analysis showed high potential for publication bias, blinding, and lack of detailed reporting on 
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CV-related events indicating low to moderate quality of evidence. Funnel plots with trim and fill 
assessed publication bias which suggested trials favoring placebo may be absent. Random effects 
model I2 statistic was used to assess heterogeneity with fixed effects models for I2 below 30%. 
Meta-analysis regression with inverse variance weighing was utilized for consistency. Results 
indicated an increase of cardiovascular events with TTh in the fixed effect model (OR 1.54, 95% 
CI 1.09 to 2.18). Trim and fill revised the OR to 1.69 (95% CI 1.21 to 2.38). When isolating 
serious events only, the OR was 1.61 (95% CI 1.01 to 2.56) with a trim and fill OR 2.01 (95% CI 
1.30 to 3.14). Overall combined cardiovascular events resulted in an OR 1.57 (95% 0.78 to 3.13) 
(figure 2.). A further subset evaluation by this study found that trials funded by the 
pharmaceutical industry resulted in half the cardiovascular events of non-industry funded studies 
(4% vs. 8%). The authors reported little heterogeneity in the studies with I2 at 7.8%. 
 
 Corona et al14 (2014) performed a systematic review and meta-analysis on RCT’s on the 
effect of TTh on cardiovascular events from Jan. 1969 to Jan. 2014. Seventy-five RCT’s utilizing 
5464 men for a mean duration of 34 weeks were evaluated. Mean age was 59.9 years with 
baseline testosterone levels at 11.2 nmol/l (~320 ng/dL). Inclusion criteria consisted of placebo-
controlled RCT’s comparing TTh to placebo for CV events. Exclusions included studies not 
specifically stating CV events, androgens other than testosterone, simultaneous therapeutic drug 
use, and use of phosphodiesterase type 5 inhibitors. Specifically, the study’s primary outcome 
was to identify the effect of TTh on new major adverse cardiovascular events (MACE) with 
secondary outcome reporting of all CV related events codified by ICD-10 criteria. MACE was 
defined as CV death, MI, stroke, acute coronary syndrome (ACS) or heart failure (HF). Quality 
assessment was made using Cochrane criteria and GRADE on randomization, allocation 
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concealment, blinding, loss to follow up, intention to treat analysis, and missing outcome data 
analysis. Further assessment was made regarding funding, population selection, and route of TTh 
administration. The overall quality of included RCTs graded as moderate to high quality, with 9 
of the studies grading low or very low quality. Heterogeneity was assessed by I2 statistics with 
random-effects model. Meta-regression analysis and funnel plots were used to test the effect of 
TTh related MACE and publication bias. Results of the study indicated no significant increase in 
MACE (OR 1.01 95% CI 0.57 to 1.77) or CV related events (OR 1.07 95% CI 0.69 to 1.65) 
(figure 3.). Further analysis of subpopulations for elderly, pre-existing cardiovascular disease 
(CVD), frailty, T-levels, duration, and funding did not show a statistically significant difference 
in MACE.     
 
 Borst et al15 (2014) completed a dual meta-analysis testing both CV adverse effects and 
the effect of TTh on serum testosterone and dihydrotestosterone (DHT). The primary outcome 
for the study was identified as any CV related events defined by the RCTs per ICD-10 codes. 
Secondary outcomes looked at the serum T and DHT levels following TTh delivered by various 
routes of administration. The CV adverse effects arm identified 35 placebo-controlled RCTs 
(3703 men >45yrs) for inclusion reporting CV-related events for both TTh and placebo groups 
after use greater than 12 weeks. Thirty-two of the RCTs reported on testosterone and DHT 
levels. Studies with testosterone suppression prior to TTh and durations of less than 12 weeks 
were excluded. The meta-analysis followed the PRISMA checklist. Quality assessment was 
evaluated using the Delphi list criteria for randomization, allocation, and blinding. Overall 
quality is rated moderate to low quality due to risk of bias. The meta-analysis was performed 
using the weighted random effects method due to sample size and RR vs OR was employed. 
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Results of the study showed CV-related events at 6.2% for TTh and 5.5% for placebo. Among 
men in the TTh arm, RR for CV events was 1.28 (95% CI 0.76 to 2.13, p=0.34) (figure 4.). 
Interestingly, CV events did vary by route of TTh administration. Oral TTh significantly 
increased CV events RR 2.20 (95% CI 1.45 to 3.35, P=0.32) (figure 4.). No significant increase 
in risk was associated with intramuscular or transdermal testosterone. Evaluation of serum T and 
DHT levels showed IM delivery raised the levels congruently while both transdermal and oral 
compounds increased DHT levels significantly compared to testosterone. The authors finding 
concerning oral TTh risk was speculated as due to the expression of 5-α reductase in the skin and 
liver which converts testosterone to DHT. Additionally, higher levels of DHT have recently been 
independently implicated to increases in CV risk16. Limitations of this study include ambiguity 
defining CV adverse effects. Data on oral preparations was also limited and must be interpreted 
with caution.  
 
 Albert & Morley17 (2016) This study’s primary aim was to determine CV events related 
to age and mode of administration. The systematic review and meta-analysis identified 45 
RCT’s, 35 from previous studies included in Xu et al, Borst et al, and Corona et al. An additional 
10 studies from 2013 to 2016 were included that were not a part of the Xu and Borst list. A total 
of 5328 patients with a mean age of 63.3 years were followed for an average of 10.6 months at T 
levels of <12 nmol/l (~345 ng/dL). CV events were defined prior to initiation as death, MI, ACS, 
percutaneous coronary intervention, coronary bypass, syncope, arrhythmia, and hospitalization 
for HF/stroke. GRADE criteria were used to evaluate quality (rated high for large RCT’s, 
Medium for post hoc analysis of CV events, and low for observational or retrospective studies). 
Funnel plots were used to identify publication bias and heterogeneity was calculated by I2 (0-
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30% low, 30-60% mod). Meta-analysis assessed mean difference with a fixed effect model. 
Overall results of the study showed no statistically significant increase in CV related events (RR 
1.10 95% CI 0.86 to 1.46, P=0.45) (figure 5.). Outcomes did not change for overall risk based on 
TTh mode, initial T levels, or therapeutic T levels. However, a higher association of risk was 
prevalent in the first 12 months of TTh with RR 1.79 95% CI 1.13 to 2.82, p=0.012). Among 
older men (>65) within the first 12 months RR was 2.90 (95% CI 1.35 to 6.21, p=0.006, I2=0%). 
No publication bias was found based on funnel plot analysis. Limitations of this study include 
reporting using poorly defined CV-related events, as well as no identifiable predisposing factors 
for the age-related findings within the first 12 months.  
 
 Alexander et al18 (2017) reviewed 39 RCTs and 10 observational studies with the 
primary goal of evaluating associated increased risk of serious CV events. Meta-analysis 
evaluated data from 30 RCTs (3230 patients). Inclusion criteria encompassed both RCT’s and 
observational studies of men 18 years and older (50 – 60 mean age range) with a minimum of 10 
participants comparing pre- and post-treatment testosterone levels to placebo or comparator for 
>3 days. Exclusions included studies containing patients with HIV, cancer, end-stage renal 
disease, schizophrenia, or primary hypogonadism. Primary outcomes reviewed were all cause 
mortality, MI, or stroke. Secondary outcomes identified other CV events such as arrhythmias, 
coronary angiography, pulmonary embolism (PE), or venous thrombosis. Quality assessment for 
RCT’s was made using Cochrane risk of bias to evaluate demographics, details of 
treatment/control groups, randomization, masking, and funding. Non-randomized studies were 
evaluated by Newcastle and Ottawa scale methods. Strength of evidence was conducted by 
GRADE criteria for imprecision, inconsistency, indirectness, and publication bias. Overall 
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quality was rated as low due to risk of bias in RCTs and imprecision. Heterogeneity was assessed 
by I2 statistics with >50% being substantial to remove from quantitative analysis. Meta- analysis 
used the fixed-effects model to calculate OR with 95% CI. Publication bias was evaluated by 
funnel plot and Eggers and Beggs-Mazumdar test, with >10 studies included. Composite results 
of MI, stroke, and death showed no significant increase in risk OR 0.96 (95% CI 0.65 to 1.42, 
I2=35.9%) (figure 6.). Individually, no increased risk was associated with MI OR 0.87 (95% CI 
0.39 to 1.93, I2=36.4%), stroke OR 2.17 (95% CI 0.63 to 7.54, I2=29.9%), or death OR 0.88 
(95% CI 0.55 to 1.41, I2=7.7%). Subgroup analysis for patients with type II diabetes (T2DM) or 
pre-existing CVD did not show a statistically significant increase in risk associated with TTh. 
Overall quality of evidence was rated as low due to risk of bias and imprecision. Limitations of 
the study include lack of patient level data and ambiguous reporting on CV related events 
without predefined criteria. Funding sources were not evaluated; however, no apparent 
publication bias was noted.             
 
Discussion 
 Final judgement on the safety and effectiveness of testosterone therapy is still unresolved 
in the eyes of many researchers and practitioners. The health benefits of TTh in hypogonadal 
men with testosterone levels <300 ng/dL (~10.5 nmol/L) have been well established in the 
literature and include increased muscle mass, increased bone density, decreased body fat, and 
improved sexual function19–23. Conversely, the side effect profile for all modalities includes 
elevated hemoglobin/hematocrit and minimal increases in PSA without associated increased risk 
of prostate cancer24–26. Only a few studies suggest a detrimental effect on CV risk. One of the 
primary observational studies to suggest TTh increases CV adverse effects reported all case side 
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effects including minor self-reported episodes of syncope or edema that may or may not have 
resulted from therapy23,27. In addition, another study did show a significant increase in CV events 
in patients treated at dosing levels well above recommended guidelines7. Overall comparisons of 
systematic reviews show no statistically significant combined association with increased CV risk 
or related events. Only one of the studies Xu et al13, indicated a statistically significant elevated 
risk but was later reevaluated and showed flawed statistical analysis based on the small number 
of reported CV events. That re-evaluation then supported the results of the other studies 
regarding CV-related events14,15. Borst found that oral TTh may increase CV risk but this data 
was taken from only 4 studies and may not have provided enough information for appropriate 
analysis15. Albert & Morley’s review discovered a potential elevated risk in >65-year-old men 
within the first 12 months of treatment; however, longer term use over 36 months did not raise 
risk. All studies stated deficiencies in reporting CV adverse effects by reviewed RCTs. The clear 
majority of the RCTs examined poorly defined parameters for what they considered CV-related 
events, skewing the distinction between related vs unrelated events. Meta-analyses presented in 
this review all sought to overcome this discrepancy by primarily looking at severe cardiac events 
as a separate study arm along with a composite analysis for overall risk.  
 Surprisingly, emerging data suggest that the CV benefits of TTh may outweigh the 
suspected risk associated with TTh especially in patients with associated cardiovascular co-
morbidities. Patients with metabolic syndrome and T2DM treated with TTh have shown marked 
improvements in CV risk factors such as central obesity, increased high-density lipoprotein 
(HDL), and insulin sensitivity20. New evidence suggests heart failure patients could benefit from 
TTh. In a study by Webb et al, TTh resulted in increased left ventricular ejection fraction 
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(LVEF) without increasing LV hypertrophy or affecting cardiac volumes28. It was also noted to 
reduce both central and peripheral arterial stiffness28.  
 Clearly, with the number of sub-populations within the demographic of potential TTh 
patients regarding age and co-morbidities, more specific placebo-controlled trials need to be 
completed. Current evidence shows no direct, or at best a weak, association with CV risk and 
TTh and in some populations, may be protective. As such, TTh should be considered in 
individuals when appropriately diagnosed with low T, symptom improvement can be objectively 
monitored, and when careful planned follow up is in place.         
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Appendix 1. – Forest Plots from meta-analysis. 
 
 
Figure 1. –  Fernandez-Balsells et al combined CV-related mortality risk. 
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Figure 2. – Xu et al, Overall combined effect from RCTs on CV-related events. 
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Figure 3. – Corona odds ratio for MACE in patients treated with TTh or placebo. 
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Figure 4. - Borst et al, combined CV-related risk from RCTs and individual CV-related risk by 
TTh treatment administration.  
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Figure 5. – Albert & Morley, overall relative risk of CV-related events.  
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Figure 6. – Alexander et al, combined CV-related risk with TTh. 
 
 
